Hydroxymethylglutaryl-CoA Reductase Inhibitors
"Hydroxymethylglutaryl-CoA Reductase Inhibitors" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Compounds that inhibit HMG-CoA reductases. They have been shown to directly lower cholesterol synthesis.
| Descriptor ID |
D019161
|
| MeSH Number(s) |
D27.505.519.186.071.202.370 D27.505.519.389.370 D27.505.954.557.500.202.370
|
| Concept/Terms |
Hydroxymethylglutaryl-CoA Reductase Inhibitors- Hydroxymethylglutaryl-CoA Reductase Inhibitors
- Hydroxymethylglutaryl CoA Reductase Inhibitors
- Inhibitors, Hydroxymethylglutaryl-CoA Reductase
- Reductase Inhibitors, Hydroxymethylglutaryl-CoA
- Inhibitors, HMG-CoA Reductase
- Inhibitors, HMG CoA Reductase
- Reductase Inhibitors, HMG-CoA
- HMG-CoA Reductase Inhibitors
- HMG CoA Reductase Inhibitors
- Statins, HMG-CoA
- HMG-CoA Statins
- Statins, HMG CoA
- Inhibitors, Hydroxymethylglutaryl-CoA
- Hydroxymethylglutaryl-CoA Inhibitors
- Inhibitors, Hydroxymethylglutaryl CoA
- Statins
- Inhibitors, Hydroxymethylglutaryl-Coenzyme A
- Hydroxymethylglutaryl-Coenzyme A Inhibitors
- Inhibitors, Hydroxymethylglutaryl Coenzyme A
|
Below are MeSH descriptors whose meaning is more general than "Hydroxymethylglutaryl-CoA Reductase Inhibitors".
Below are MeSH descriptors whose meaning is more specific than "Hydroxymethylglutaryl-CoA Reductase Inhibitors".
This graph shows the total number of publications written about "Hydroxymethylglutaryl-CoA Reductase Inhibitors" by people in this website by year, and whether "Hydroxymethylglutaryl-CoA Reductase Inhibitors" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 1 | 2 | 3 |
| 1997 | 0 | 1 | 1 |
| 1998 | 3 | 0 | 3 |
| 1999 | 3 | 0 | 3 |
| 2000 | 3 | 0 | 3 |
| 2001 | 6 | 0 | 6 |
| 2002 | 4 | 1 | 5 |
| 2003 | 5 | 6 | 11 |
| 2004 | 8 | 3 | 11 |
| 2005 | 10 | 1 | 11 |
| 2006 | 9 | 5 | 14 |
| 2007 | 16 | 5 | 21 |
| 2008 | 12 | 2 | 14 |
| 2009 | 9 | 0 | 9 |
| 2010 | 13 | 3 | 16 |
| 2011 | 12 | 8 | 20 |
| 2012 | 8 | 3 | 11 |
| 2013 | 19 | 3 | 22 |
| 2014 | 17 | 10 | 27 |
| 2015 | 18 | 7 | 25 |
| 2016 | 21 | 12 | 33 |
| 2017 | 16 | 6 | 22 |
| 2018 | 29 | 7 | 36 |
| 2019 | 31 | 15 | 46 |
| 2020 | 14 | 5 | 19 |
| 2021 | 28 | 7 | 35 |
| 2022 | 36 | 0 | 36 |
| 2023 | 22 | 0 | 22 |
| 2024 | 7 | 3 | 10 |
| 2025 | 10 | 6 | 16 |
| 2026 | 2 | 1 | 3 |
To return to the timeline,
click here.
Below are the most recent publications written about "Hydroxymethylglutaryl-CoA Reductase Inhibitors" by people in Profiles.
-
Statin Use and Recurrent Atherosclerotic Cardiovascular Disease Events in Patients With Coronary Artery Intervention: A Retrospective Analysis From a Large Health Care Network. J Am Heart Assoc. 2026 Mar 17; 15(6):e041416.
-
Intracoronary Imaging and Transcriptomic Characteristics Before and After Maximum Lipid-Lowering Therapy: YELLOW-III Study of Evolocumab and Maximum Statin Therapy in Chronic Coronary Disease. JACC Cardiovasc Imaging. 2026 Apr; 19(4):516-534.
-
Efficacy and Safety of Oral PCSK9 Inhibitor Enlicitide in Adults With Heterozygous Familial Hypercholesterolemia: A Randomized Clinical Trial. JAMA. 2026 01 13; 335(2):129-139.
-
A multicenter trial to test pitavastatin calcium in youth with combined dyslipidemia of obesity: Design, implementation, challenges, and responses. Am Heart J. 2026 Apr; 294:107327.
-
Lipid-lowering therapies to target cardiac allograft vasculopathy after heart transplantation: Current evidence and future directions. J Clin Lipidol. 2026 Feb; 20(2):262-269.
-
The evolving landscape of targets for lipid lowering: from molecular mechanisms to translational implications. Eur Heart J. 2025 Nov 21; 46(44):4737-4750.
-
Lp(a) testing for the primary prevention of cardiovascular disease in high-income countries: a cost-effectiveness analysis. Atherosclerosis. 2025 Oct; 409:120447.
-
No evidence of pitavastatin effect on muscle area or density among people with HIV. AIDS. 2025 Nov 15; 39(14):2031-2039.
-
Clinical impact of pharmacogenetic risk variants in a large chinese cohort. Nat Commun. 2025 Jul 09; 16(1):6344.
-
Treatment of severe hyperlipidemia and associated cardiovascular outcomes: Data from a large healthcare system. J Clin Lipidol. 2025 Sep-Oct; 19(5):1256-1263.